25-Valent Pneumococcal Conjugate Vaccine Candidate Launches Early Stage Study

Inventprise recently announced that a first-in-human Phase 1/2 clinical study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) has begun in Halifax, Canada. 

This vaccine candidate is designed to prevent pneumococcal disease caused by serotypes not covered in the current vaccines.

The Phase 1 portion of the study now underway will enroll healthy adult volunteers and use an authorized adult 20-valent PCV as the comparator.

Satisfactory Phase 1 results will trigger Phase 2, which will evaluate the IVT PCV-25, first in young children and then, pending satisfactory data, in infants.

Phase 2 will use an authorized infant 13-valent PCV as the comparator.

“This Phase 1/2 study is important to determine how IVT PCV-25 performs in people and will inform decisions around the vaccine’s progression into later-stage clinical development,” says Dr. Joanne Langley, the study’s principal investigator, in a press release on November 10, 2022.

“If studies show that the vaccine can safely protect against more types of pneumococcal disease, it could be a meaningful tool in the fight against pneumonia—the long-reigning leading cause of child death due to infectious disease in the world.”

Sponsored by Inventprise and conducted in collaboration with the international nonprofit organization PATH and the Canadian Immunization Research Network.

Additional pneumococcal vaccine information is posted at PrecisionVaccinations.com/Pneumococcal.